ACIpharma
-
RT @ News: Another Loss for Pfizer in Hormone Drug Suits
about 15 hours ago
from web
-
RT @ Medicis takes Lupin to on patent charge:Medicis Pharmaceutical Corporation has filed a case
10:10 AM Nov 24th
from web
-
Pfizer Hit With $6.3M Prempro Verdict In Pa.
11:18 AM Nov 23rd
from web
-
Device makers get fee cut.
10:00 AM Nov 23rd
from web
-
@ Court Mulls Class Decertification in Off-Label Drug Case
8:39 AM Nov 23rd
from web
in reply to Dr_Arndt
-
Pharmaceutical makers look for ingredients closer to home
11:14 AM Nov 19th
from web
-
Top Five Compliance Risks Facing Life Life Sciences Companies.
1:56 PM Nov 18th
from web
-
Pharma's money grab: Steep price hikes before reform kicks in
9:50 AM Nov 18th
from web
-
Democrats about to antagonize drug makers:
10:08 AM Nov 17th
from web
-
Exams for governance boards on quality measures could be a way to improve care, accountability in hospitals
1:38 PM Nov 16th
from web
-
RT @. Big Pharma Willing to Pay for Biotech Innovation
7:48 PM Nov 15th
from web
-
Big Pharma still hungry for biotech deals: (Reuters) Biotech is the engine for innovation in the drug industry
11:47 AM Nov 12th
from web
-
Infosint Seeks Increased Damages Award in Citalopram Suit
11:41 AM Nov 12th
from web
-
Big pharma and BIotech: (M&A) and in-licensing deals to make up for the loss of revenues.
10:44 AM Nov 10th
from web
-
DC Vaccine Conference: all aspects of vaccine research, development, regulations, and policy to be discussed.
12:27 PM Nov 9th
from web
-
12 Senators Write in Support of 12-Year Data Exclusivity Period -
9:15 AM Nov 4th
from web
-
Amylin and Takeda sign licensing and development agreement -
8:31 AM Nov 3rd
from web
-
BRCA Patent Suit to Continue in Southern District of New York -
7:50 AM Nov 3rd
from web
-
In Which You Get to Hear the Phrase "Hatch-Waxman" Again -
12:15 PM Nov 2nd
from web
-
Follow-on Biologics Data Exclusivity Debate Scorecard - Part I -
10:17 AM Oct 29th
from web
|
- Name ACI pharma
- Web http://www.americ...
- Bio ACI is the leading provider of continuing legal, business, and policy-driven education programs for the pharmaceutical, biotech and life sciences industries.
|